Predictive Factors for a Successful Treatment Outcome in Patients with Different Voiding Dysfunction Subtypes Who Received Urethral Sphincter Botulinum Injection
Abstract
1. Introduction
2. Results
3. Discussion
4. Conclusions
5. Materials and Methods
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Appendix A
Female (n = 77) | Male (n = 26) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
DV (n = 70) | PRES (n = 7) | pa | DV (n = 13) | PRES (n = 13) | p a | ||||||
Age | 54.7 | ±22.7 | 70.6 | ±8.2 * | 63.1 | ±12.9 | 74.4 | ±12.9* | |||
VUDS parameters | |||||||||||
FSF (mL) | B | 104.6 | ±62.4 | 93.9 | ±39.5 | 119.5 | ±52.7 | 172.8 | ±111.4 | ||
P | 123.6 | ±75.2 | 142.7 | ±70.4 | 0.518 | 123.0 | ±66.4 | 178.5 | ±60.3 * | 0.038 | |
FS (mL) | B | 171.6 | ±80.8 | 156.9 | ±57.8 | 208.6 | ±103.9 | 289.0 | ±118.4 | ||
P | 193.2 | ±99.4 | 192.7 | ±90.8 | 0.990 | 203.2 | ±140.1 | 300.0 | ±112.7 | 0.059 | |
US (mL) | B | 205.9 | ±100.2 | 190.4 | ±80.8 | 234.4 | ±119.2 | 333.4 | ±112.5 * | ||
P | 219.0 | ±111.0 | 229.6 | ±101.2 | 0.794 | 203.8 | ±132.3 | 359.3 | ±107.1 * | 0.003 | |
Compliance | B | 41.6 | ±56.6 | 92.5 | ±96.8 | 45.5 | ±60.5 | 43.5 | ±22.0 | ||
(mL/cm H2O) | P | 57.3 | ±67.4 | 46.8 | ±23.4 | 0.675 | 67.3 | ±68.6 | 45.6 | ±19.8 | 0.281 |
DO | B | 48 | (69) | 3 | (43) | 8 | (62) | 1 | (8) * | ||
P | 41 | (59) | 1 | (14) * | 0.081 | 11 | (85) | 2 | (15) * | 0.016 | |
Pdet | B | 56.0 | ±33.0 | 41.3 | ±60.7 | 34.7 | ±14.5 | 13.8 | ±13.7 * | ||
(cm H2O) | P | 48.2 | ±34.3 | 18.1 | ±9.6 * | 0.001 | 31.8 | ±17.5 | 15.2 | ±12.9 * | 0.003 |
Qmax (mL/s) | B | 6.0 | ±4.4 | 10.9 | ±7.0 * | 6.5 | ±6.1 | 4.4 | ±4.4 | ||
P | 6.4 | ±5.1 | 12.3 | ±6.5 * | 0.003 | 9.0 | ±6.2 | 4.5 | ±5.0 | 0.040 | |
BOOI | B | 44.0 | ±33.3 | 19.6 | ±66.4 | 21.6 | ±16.0 | 5.0 | ±12.7 * | ||
P | 35.4 | ±35.3 | −6.4 | ±13.4 * | <0.001 | 13.8 | ±15.9 | 6.2 | ±13.7 | 0.208 | |
VV (mL) | B | 119.7 | ±103.0 | 168.9 | ±91.8 | 148.3 | ±132.0 | 128.6 | ±146.6 | ||
P | 122.9 | ±112.6 | 298.4 | ±127.1 * | <0.001 | 163.2 | ±136.0 | 113.9 | ±166.0 | 0.345 | |
PVR (mL) | B | 188.6 | ±142.8 | 175.7 | ±153.2 | 207.8 | ±184.5 | 266.9 | ±170.2 | ||
P | 211.1 | ±156.9 | 100.0 | ±155.5 | 0.070 | 181.2 | ±206.7 | 281.1 | ±168.9 | 0.090 | |
BVE (%) | B | 41.2 | ±31.8 | 54.1 | ±33.6 | 46.3 | ±31.00 | 33.8 | ±39.2 | ||
P | 41.4 | ±34.5 | 82.4 | ±26.5 * | 0.002 | 59.2 | ±39.0 | 29.1 | ±34.2 | 0.022 | |
Global Response Assessment | |||||||||||
Excellent | 19 | (27) | 1 | (14) | 3 | (23) | 4 | (31) | |||
Markedly improve | 33 | (47) | 4 | (57) | 7 | (54) | 5 | (38) | |||
Mildly improve | 5 | (7) | 0 | (0) | 1 | (8) | 0 | (0) | |||
No change | 12 | (17) | 2 | (29) | 2 | (15) | 4 | (31) | |||
Missing | 1 | (1) | 0 | (0) | 0 | (0) | 0 | (0) | |||
Successful outcome b | 52 | (74) | 5 | (71) | 1.000 | 10 | (77) | 9 | (69) | 1.000 |
References
- Haylen, B.T.; Maher, C.F.; Barber, M.D.; Camargo, S.; Dandolu, V.; Digesu, A.; Goldman, H.B.; Huser, M.; Milani, A.L.; Moran, P.A.; et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic organ prolapse (POP). Int. Urogynecol. J. 2016, 27, 165–194. [Google Scholar] [CrossRef] [PubMed]
- D’Ancona, C.; Haylen, B.; Oelke, M.; Abranches-Monteiro, L.; Arnold, E.; Goldman, H.; Hamid, R.; Homma, Y.; Marcelissen, T.; Rademakers, K.; et al. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol. Urodyn. 2019, 38, 433–477. [Google Scholar] [CrossRef] [PubMed]
- Choi, Y.S.; Kim, J.C.; Lee, K.S.; Seo, J.T.; Kim, H.J.; Yoo, T.K.; Lee, J.B.; Choo, M.S.; Lee, J.G.; Lee, J.Y. Analysis of female voiding dysfunction: A prospective, multi-center study. Int. Urol. Nephrol. 2013, 45, 989–994. [Google Scholar] [CrossRef] [PubMed]
- Kuo, H.C. Botulinun A toxin urethral sphincter injection for neurogenic or nonneurogenic voiding dysfunction. Ci Ji Yi Xue Za Zhi 2016, 28, 89–93. [Google Scholar] [CrossRef]
- Winters, J.C.; Dmochowski, R.R.; Goldman, H.B.; Herndon, C.D.; Kobashi, K.C.; Kraus, S.R.; Lemack, G.E.; Nitti, V.W.; Rovner, E.S.; Wein, A.J. Urodynamic studies in adults: AUA/SUFU guideline. J. Urol. 2012, 188, 2464–2472. [Google Scholar] [CrossRef]
- Kuo, H.C. Videourodynamic characteristics and lower urinary tract symptoms of female bladder outlet obstruction. Urology 2005, 66, 1005–1009. [Google Scholar] [CrossRef]
- Jiang, Y.H.; Chen, S.F.; Kuo, H.C. Role of videourodynamic study in precision diagnosis and treatment for lower urinary tract dysfunction. Ci Ji Yi Xue Za Zhi 2020, 32, 121–130. [Google Scholar] [CrossRef]
- Dykstra, D.D.; Sidi, A.A.; Scott, A.B.; Pagel, J.M.; Goldish, G.D. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J. Urol. 1988, 139, 919–922. [Google Scholar] [CrossRef]
- Kao, Y.L.; Huang, K.H.; Kuo, H.C.; Ou, Y.C. The Therapeutic Effects and Pathophysiology of Botulinum Toxin A on Voiding Dysfunction Due to Urethral Sphincter Dysfunction. Toxins 2019, 11, 728. [Google Scholar] [CrossRef]
- Jiang, Y.H.; Wang, C.C.; Kuo, H.C. OnabotulinumtoxinA Urethral Sphincter Injection as Treatment for Non-neurogenic Voiding Dysfunction—A Randomized, Double-Blind, Placebo-Controlled Study. Sci. Rep. 2016, 6, 38905. [Google Scholar] [CrossRef]
- Lee, C.L.; Chen, S.F.; Jiang, Y.H.; Kuo, H.C. Effect of videourodynamic subtypes on treatment outcomes of female dysfunctional voiding. Int. Urogynecol. J. 2022, 33, 1283–1291. [Google Scholar] [CrossRef]
- Dykstra, D.D.; Sidi, A.A. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: A double-blind study. Arch. Phys. Med. Rehabil. 1990, 71, 24–26. [Google Scholar]
- Moore, D.C.; Cohn, J.A.; Dmochowski, R.R. Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature. Toxins 2016, 8, 88. [Google Scholar] [CrossRef] [PubMed]
- Nadeem, M.; Lindsay, J.; Pakzad, M.; Hamid, R.; Ockrim, J.; Greenwell, T. Botulinum toxin A injection to the external urethral sphincter for voiding dysfunction in females: A tertiary center experience. Neurourol. Urodyn. 2022, 41, 1793–1799. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.K.; Kuo, H.C. Therapeutic Effects of Botulinum Toxin A, via Urethral Sphincter Injection on Voiding Dysfunction Due to Different Bladder and Urethral Sphincter Dysfunctions. Toxins 2019, 11, 487. [Google Scholar] [CrossRef] [PubMed]
- Liao, Y.M.; Kuo, H.C. Causes of failed urethral botulinum toxin A treatment for emptying failure. Urology 2007, 70, 763–766. [Google Scholar] [CrossRef]
- Ou, Y.C.; Huang, K.H.; Jan, H.C.; Kuo, H.C.; Kao, Y.L.; Tsai, K.J. Therapeutic Efficacy of Urethral Sphincteric Botulinum Toxin Injections for Female Sphincter Dysfunctions and a Search for Predictive Factors. Toxins 2021, 13, 398. [Google Scholar] [CrossRef]
- Jiang, Y.H.; Chen, S.F.; Kuo, H.C. Frontiers in the Clinical Applications of Botulinum Toxin A as Treatment for Neurogenic Lower Urinary Tract Dysfunction. Int. Neurourol. J. 2020, 24, 301–312. [Google Scholar] [CrossRef]
- Mehta, S.; Hill, D.; Foley, N.; Hsieh, J.; Ethans, K.; Potter, P.; Baverstock, R.; Teasell, R.W.; Wolfe, D. A meta-analysis of botulinum toxin sphincteric injections in the treatment of incomplete voiding after spinal cord injury. Arch. Phys. Med. Rehabil. 2012, 93, 597–603. [Google Scholar] [CrossRef]
- Franco, I.; Landau-Dyer, L.; Isom-Batz, G.; Collett, T.; Reda, E.F. The use of botulinum toxin A injection for the management of external sphincter dyssynergia in neurologically normal children. J. Urol. 2007, 178, 1775–1779; discussion 1779–1780. [Google Scholar] [CrossRef]
- Wein, A.; Rovner, E. Adult voiding dysfunction secondary to neurologic disease or injury. AUA Update Ser. 1999, 18, 42–48. [Google Scholar]
- Panicker, J.N. Neurogenic Bladder: Epidemiology, Diagnosis, and Management. Semin Neurol 2020, 40, 569–579. [Google Scholar] [CrossRef] [PubMed]
- Chapple, C. International Continence Society guidelines on urodynamic equipment performance. Neurourol. Urodyn. 2014, 33, 369. [Google Scholar] [CrossRef] [PubMed]
- Austin, P.F.; Bauer, S.B.; Bower, W.; Chase, J.; Franco, I.; Hoebeke, P.; Rittig, S.; Walle, J.V.; von Gontard, A.; Wright, A.; et al. The standardization of terminology of lower urinary tract function in children and adolescents: Update report from the standardization committee of the International Children’s Continence Society. Neurourol. Urodyn. 2016, 35, 471–481. [Google Scholar] [CrossRef] [PubMed]
- Hsiao, S.M.; Lin, H.H.; Kuo, H.C. Videourodynamic Studies of Women with Voiding Dysfunction. Sci. Rep. 2017, 7, 6845. [Google Scholar] [CrossRef]
- Abrams, P. Bladder outlet obstruction index, bladder contractility index and bladder voiding efficiency: Three simple indices to define bladder voiding function. BJU Int. 1999, 84, 14–15. [Google Scholar] [CrossRef]
- Deindl, F.M.; Vodusek, D.B.; Bischoff, C.; Hofmann, R.; Hartung, R. Dysfunctional voiding in women: Which muscles are responsible? Br. J. Urol. 1998, 82, 814–819. [Google Scholar] [CrossRef]
- Kuo, Y.C.; Kuo, H.C. Botulinum toxin injection for lower urinary tract dysfunction. Int. J. Urol. 2013, 20, 40–55. [Google Scholar] [CrossRef]
Female (n = 138) | Male (n = 43) | p Value | |||
---|---|---|---|---|---|
Mean ± SD or No. (%) | Mean ± SD or No. (%) | ||||
Age | 59.7 | ±21.1 | 67.3 | ±14.0 | 0.003 |
Diagnosis | |||||
Detrusor underactivity | 61 | (44) | 17 | (40) | |
Urethral sphincter dysfunction * | 77 | (56) | 26 | (60) | 0.589 |
Diabetes mellitus | 36 | (26) | 11 | (26) | 0.947 |
Hypertension | 65 | (47) | 18 | (42) | 0.547 |
CAD | 13 | (9) | 1 | (2) | 0.193 |
CKD | 3 | (2) | 1 | (2) | 1.000 |
COPD | 1 | (2) | 0.238 | ||
Parkinson disease | 2 | (1) | 6 | (14) | 0.003 |
CVA | 19 | (14) | 7 | (16) | 0.682 |
Dementia | 1 | (1) | 3 | (7) | 0.042 |
Recurrent UTI | 47 | (34) | 2 | (5) | <0.001 |
History of TURP | 24 | (56) | <0.001 | ||
History of TUI-BN | 69 | (50) | 8 | (19) | <0.001 |
Female (n = 138) | Detrusor Underactivity | Urethral Sphincter Dysfunction * | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Before Urethral Botox Injection (n = 61) | After Urethral Botox Injection (n = 61) | p Value | Before Urethral Botox Injection (n = 77) | After Urethral Botox Injection (n = 77) | p Value | |||||
Mean ± SD or No. (%) | Mean ± SD or No. (%) | Mean ± SD or No. (%) | Mean ± SD or No. (%) | |||||||
VUDS parameters | ||||||||||
FSF (mL) | 177.3 | ±76.6 | 158.6 | 78.2 | 0.152 | 103.6 | ±60.5 | 125.3 | ±74.6 | 0.034 |
FS (mL) | 250.1 | ±86.4 | 230.0 | 104.6 | 0.142 | 170.3 | ±78.8 | 193.2 | ±98.1 | 0.059 |
US (mL) | 295.7 | ±106.5 | 266.3 | 109.6 | 0.042 | 204.5 | ±98.3 | 219.9 | ±109.5 | 0.242 |
Compliance (mL/cm H2O) | 64.3 | ±80.1 | 58.0 | 50.4 | 0.585 | 46.3 | ±62.2 | 56.3 | ±64.6 | 0.258 |
DO | 7 | (11) | 6 | (10) | 0.655 | 51 | (66) | 42 | (55) | 0.083 |
Pdet(cm H2O) | 6.4 | ±7.9 | 7.2 | ±11.1 | 0.573 | 54.7 | ±36.0 | 45.5 | ±33.9 | 0.009 |
Qmax (mL/s) | 4.0 | ±7.1 | 4.9 | ±6.5 | 0.460 | 6.5 | ±4.9 | 6.9 | ±5.5 | 0.430 |
BOOI | −1.4 | ±16.4 | −2.5 | ±13.7 | 0.623 | 41.8 | ±37.5 | 31.6 | ±35.9 | 0.010 |
VV (mL) | 89.3 | ±131.5 | 101.0 | ±139.5 | 0.596 | 124.2 | ±102.5 | 138.8 | ±124.0 | 0.337 |
PVR (mL) | 315.4 | ±210.5 | 313.3 | ±220.5 | 0.952 | 187.4 | ±142.8 | 200.9 | ±159.0 | 0.480 |
BVE (%) | 21.5 | ±30.9 | 26.1 | ±35.0 | 0.402 | 42.4 | ±31.9 | 45.1 | ±35.8 | 0.540 |
Global Response Assessment | ||||||||||
Excellent | 5 | (8) | 20 | (26) | ||||||
Markedly improved | 29 | (48) | 37 | (48) | ||||||
Mildly improved | 8 | (13) | 5 | (6) | ||||||
No change | 18 | (30) | 14 | (18) | ||||||
Missing | 1 | (2) | 1 | (1) | 0.024 b | |||||
Successful outcome a | 34 | (56) | 57 | (74) | 0.024 b |
Male (n = 43) | Detrusor Underactivity | Urethral Sphincter Dysfunction * | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Before Urethral Botox Injection (n = 17) | After Urethral Botox Injection (n = 17) | p Value | Before Urethral Botox Injection (n = 26) | After Urethral Botox Injection (n = 26) | p Value | |||||
Mean ± SD or No. (%) | Mean ± SD or No. (%) | Mean ± SD or No. (%) | Mean ± SD or No. (%) | |||||||
VUDS parameters | ||||||||||
FSF (mL) | 181.4 | ±105.9 | 172.2 | ±99.1 | 0.727 | 146.2 | ±89.6 | 150.8 | ±68.3 | 0.818 |
FS (mL) | 265.9 | ±153.0 | 275.3 | ±156.2 | 0.828 | 248.8 | ±116.6 | 251.6 | ±134.0 | 0.919 |
US (mL) | 320.6 | ±157.3 | 323.4 | ±164.4 | 0.947 | 283.9 | ±124.3 | 281.5 | ±142.1 | 0.934 |
Compliance (mL/cmH2O) | 73.5 | ±141.5 | 41.1 | ±38.0 | 0.359 | 44.5 | ±44.6 | 56.4 | ±50.7 | 0.424 |
DO | 4 | (24) | 6 | (35) | 0.157 | 9 | (35) | 13 | (50) | 0.103 |
Pdet(cm H2O) | 10.5 | ±11.0 | 18.0 | ±24.2 | 0.285 | 24.2 | ±17.5 | 23.5 | ±17.3 | 0.791 |
Qmax (mL/s) | 1.8 | ±2.6 | 2.5 | ±2.6 | 0.282 | 5.5 | ±5.3 | 6.8 | ±6.0 | 0.271 |
BOOI | 6.9 | ±9.7 | 12.9 | ±24.2 | 0.336 | 13.3 | ±16.5 | 10.0 | ±15.1 | 0.405 |
VV (mL) | 24.5 | ±40.4 | 38.9 | ±50.6 | 0.258 | 138.5 | ±137.0 | 138.6 | ±150.8 | 0.997 |
PVR (mL) | 375.3 | ±162.0 | 393.8 | ±185.4 | 0.712 | 237.4 | ±176.5 | 231.1 | ±191.8 | 0.831 |
BVE (%) | 8.2 | ±12.5 | 11.4 | ±13.7 | 0.348 | 40.1 | ±35.2 | 44.1 | ±39.0 | 0.552 |
Global Response Assessment | ||||||||||
Excellent | 3 | (18) | 7 | (27) | ||||||
Markedly improved | 3 | (18) | 12 | (46) | ||||||
Mildly improved | 1 | (6) | 1 | (4) | ||||||
No change | 10 | (59) | 6 | (23) | 0.094 b | |||||
Successful outcome a | 6 | (36) | 19 | (73) | 0.0141 b |
Univariate Analysis | Multivariate Analysis | |||||||
---|---|---|---|---|---|---|---|---|
OR | 95% CI | p Value | OR | 95% CI | p Value | |||
Age | 0.98 | 0.97 | 1.00 | 0.062 | 1.00 | 0.98 | 1.02 | 0.728 |
Gender | 0.72 | 0.36 | 1.45 | 0.353 | 0.88 | 0.38 | 2.04 | 0.769 |
DU | 0.37 | 0.20 | 0.70 | 0.002 | 0.46 | 0.21 | 0.99 | 0.047 |
Comorbidities | ||||||||
DM | 0.61 | 0.31 | 1.19 | 0.147 | ||||
HTN | 0.50 | 0.27 | 0.92 | 0.026 | 0.53 | 0.25 | 1.13 | 0.099 |
CAD | 2.17 | 0.58 | 8.06 | 0.250 | ||||
CKD | 1.70 | 0.17 | 16.66 | 0.649 | ||||
PD | 0.93 | 0.22 | 4.02 | 0.923 | ||||
CVA | 1.07 | 0.45 | 2.56 | 0.882 | ||||
Dementia | 0.55 | 0.08 | 4.02 | 0.558 | ||||
Recurrent UTI | 2.39 | 1.12 | 5.09 | 0.024 | 3.82 | 1.58 | 9.22 | 0.003 |
TURP history | 0.62 | 0.26 | 1.48 | 0.280 | ||||
TUIBN history | 0.80 | 0.43 | 1.47 | 0.462 | ||||
Baseline VUDS parameters | ||||||||
FSF (mL) | 1.00 | 0.99 | 1.00 | 0.159 | ||||
FS (mL) | 1.00 | 0.99 | 1.00 | 0.036 | 1.00 | 1.00 | 1.00 | 0.559 |
US (mL) | 1.00 | 1.00 | 1.00 | 0.164 | ||||
Compliance (mL/cm H2O) | 1.00 | 1.00 | 1.00 | 0.500 | ||||
DO | 1.59 | 0.84 | 3.00 | 0.155 | ||||
BVE (%) | 1.02 | 1.01 | 1.03 | <0.001 | 1.02 | 1.01 | 1.03 | 0.004 |
BOOI | 1.01 | 1.00 | 1.02 | 0.327 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kao, Y.-L.; Ou, Y.-C.; Tsai, K.-J.; Kuo, H.-C. Predictive Factors for a Successful Treatment Outcome in Patients with Different Voiding Dysfunction Subtypes Who Received Urethral Sphincter Botulinum Injection. Toxins 2022, 14, 877. https://doi.org/10.3390/toxins14120877
Kao Y-L, Ou Y-C, Tsai K-J, Kuo H-C. Predictive Factors for a Successful Treatment Outcome in Patients with Different Voiding Dysfunction Subtypes Who Received Urethral Sphincter Botulinum Injection. Toxins. 2022; 14(12):877. https://doi.org/10.3390/toxins14120877
Chicago/Turabian StyleKao, Yao-Lin, Yin-Chien Ou, Kuen-Jer Tsai, and Hann-Chorng Kuo. 2022. "Predictive Factors for a Successful Treatment Outcome in Patients with Different Voiding Dysfunction Subtypes Who Received Urethral Sphincter Botulinum Injection" Toxins 14, no. 12: 877. https://doi.org/10.3390/toxins14120877
APA StyleKao, Y.-L., Ou, Y.-C., Tsai, K.-J., & Kuo, H.-C. (2022). Predictive Factors for a Successful Treatment Outcome in Patients with Different Voiding Dysfunction Subtypes Who Received Urethral Sphincter Botulinum Injection. Toxins, 14(12), 877. https://doi.org/10.3390/toxins14120877